Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 19 of 19 entries
View as:

A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03377179 Org: User:
Start: 03/07/18 End: 06/21/22 Due: 06/21/23

Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)

Phase: N/A Priority: Normal
NCT ID: NCT01717664 Org: User:
Start: 06/30/13 End: 07/31/16 Due: 07/31/17

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

Phase: N/A Priority: Normal
NCT ID: NCT04026984 Org: User:
Start: 06/30/24 End: 12/31/25 Due: 12/31/26

Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen

Phase: N/A Priority: Normal
NCT ID: NCT04502069 Org: User:
Start: 08/31/20 End: 06/30/21 Due: 06/30/22

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01951326 Org: User:
Start: 09/30/13 End: 08/31/19 Due: 08/31/20

Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

Phase: N/A Priority: Normal
NCT ID: NCT04723537 Org: User:
Start: 02/16/21 End: 12/28/21 Due: 12/28/22

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03009396 Org: User:
Start: 03/18/17 End: 08/19/19 Due: 08/19/20

ABC294640 in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01488513 Org: User:
Start: 08/31/11 End: 07/31/15 Due: 07/31/16

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

Phase: N/A Priority: Normal
NCT ID: NCT04467840 Org: User:
Start: 08/21/20 End: 07/18/21 Due: 07/18/22

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

Phase: N/A Priority: Normal
NCT ID: NCT04414618 Org: User:
Start: 07/02/20 End: 12/23/20 Due: 12/23/21

ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator

Phase: N/A Priority: Normal
NCT ID: NCT03198507 Org: User:
Start: 06/18/17 End: 12/13/18 Due: 12/13/19

Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

Phase: N/A Priority: Normal
NCT ID: NCT03414489 Org: User:
Start: - End: - Due: -

Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT02229981 Org: User:
Start: 07/31/14 End: 12/31/19 Due: 12/31/20

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Phase: N/A Priority: Normal
NCT ID: NCT02757105 Org: User:
Start: 05/19/16 End: 07/14/17 Due: 07/14/18

BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis

Phase: N/A Priority: Normal
NCT ID: NCT02246439 Org: User:
Start: 12/08/14 End: 02/16/17 Due: 02/16/18

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

Phase: N/A Priority: Normal
NCT ID: NCT01980095 Org: User:
Start: 11/30/13 End: 08/31/15 Due: 08/31/16

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02757326 Org: User:
Start: 12/13/16 End: 05/31/19 Due: 05/31/20

RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease

Phase: N/A Priority: Normal
NCT ID: NCT04616924 Org: User:
Start: 12/01/20 End: 08/28/23 Due: 08/28/24

Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

Phase: N/A Priority: Normal
NCT ID: NCT04027894 Org: User:
Start: 01/31/24 End: 12/31/25 Due: 12/31/26